XFOR

X 4 Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality5/10
  • Growth↓ 0/10
  • Momentum↓ 2/10
X 4 Pharmaceuticals sales and earnings growth
XFOR Growth
Low
  • Revenue Y/Y↑ 2925.73%
  • EPS Y/Y↓ -328.81%
  • FCF Y/Y↑ 20.19%
X 4 Pharmaceuticals gross and profit margin trends
XFOR Profitability
Neutral
  • Gross margin ↑ 83.20%
  • EPS margin↓ -279.90%
  • ROIC↓ -78.30%
X 4 Pharmaceuticals net debt vs free cash flow
XFOR Risk
Good
  • Debt / Equity↓ 1.3
  • Debt / FCF↓ 0.1
  • Interest coverage↓ -9.5

X 4 Pharmaceuticals stock volatility is in-line with the overall market. We give it a Good risk rating.

More Biotechnology stocks ↗